Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended December 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2 billion, up 10.1% over the same period last year. EPS came in at $6.64, compared to $6.60 in the year-ago quarter.

The reported revenue represents a surprise of +1.56% over the Zacks Consensus Estimate of $1.18 billion. With the consensus EPS estimate being $6.62, the EPS surprise was +0.27%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total revenues- Oncology- Vyxeos: $34.73 million versus $47.69 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -34.8% change.
• Total revenues- Oncology- Defitelio/defibrotide: $58.87 million versus the six-analyst average estimate of $56.26 million. The reported number represents a year-over-year change of +2.1%.
• Total revenues- Neuroscience- Oxybate- Xywav: $465.45 million versus $448.99 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.
• Total revenues- Neuroscience- Epidiolex/Epidyolex: $287.12 million versus $297.23 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
• Total revenues- Neuroscience- Sativex: $1.5 million compared to the $5.12 million average estimate based on six analysts. The reported number represents a change of -71% year over year.
• Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $503.23 million versus the six-analyst average estimate of $481.03 million. The reported number represents a year-over-year change of +11.8%.
• Total revenues- Neuroscience- Total: $791.86 million compared to the $783.39 million average estimate based on six analysts. The reported number represents a change of +8.4% year over year.
• Total revenues- Oncology- Total: $337.28 million compared to the $322.89 million average estimate based on six analysts. The reported number represents a change of +15.6% year over year.
• Total revenues- Oncology- Rylaze/Enrylaze: $108.16 million compared to the $105.81 million average estimate based on six analysts. The reported number represents a change of +6.6% year over year.
• Total revenues- Oncology- Zepzelca: $90.44 million versus the six-analyst average estimate of $84.24 million. The reported number represents a year-over-year change of +15.5%.
• Revenues- Product sales, net: $1.13 billion versus $1.11 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
• Total revenues - Oncology - Ziihera: $8.54 million versus the six-analyst average estimate of $11.91 million.

View all Key Company Metrics for Jazz here>>>

Shares of Jazz have returned +4.2% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research